Novartis ‘Urgently’ Working To Improve Zolgensma Access Program
‘Lottery-Style’ Scheme Has Gone Down Better Outside Europe
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.
